[HTML][HTML] Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
X Pu, Y Zhou, Y Kong, B Chen, A Yang, J Li, K Li, Y Xu… - Bmc Cancer, 2023 - Springer
Background About 10% of non-small cell lung cancer (NSCLC) patients with epidermal
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
growth factor receptor (EGFR) mutations are harbored as uncommon mutations. This study …
Multidrug-Resistant Profiles in Non-Small Cell Lung Carcinoma Patient-Derived Cells: Implications for Personalized Approaches with Tyrosine Kinase Inhibitors
J Dinić, M Dragoj, S Jovanović Stojanov, A Stepanović… - Cancers, 2024 - mdpi.com
Simple Summary This research investigates the challenge of drug resistance in non-small
cell lung carcinoma (NSCLC) and how certain drugs, namely, tyrosine kinase inhibitors …
cell lung carcinoma (NSCLC) and how certain drugs, namely, tyrosine kinase inhibitors …
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data
P Cheema, BC Cho, H Freitas, M Provencio… - Future …, 2023 - Future Medicine
Aim: Report the final analysis from ASTRIS, the largest real-world study of second-/later-line
osimertinib in advanced/metastatic EGFR T790M non-small-cell lung cancer (NSCLC) …
osimertinib in advanced/metastatic EGFR T790M non-small-cell lung cancer (NSCLC) …
Electrochemical and theoretical study on interaction between erlotinib and DNA
M Jovanović, K Nikolic, M Čarapić… - Journal of Pharmaceutical …, 2023 - Elsevier
A comprehensive investigation of tyrosine kinase inhibitor erlotinib (ERL) electrochemical
behavior and interaction with DNA was performed with the aim to clarify its redox …
behavior and interaction with DNA was performed with the aim to clarify its redox …
Case report: Long-term survival with anlotinib in a metastatic parathyroid carcinoma patient harboring EGFR-sensitizing mutation
Y Ying, H Li, W Xia, T Cheng, H Li, Q Fu, T Ai, Y Yang… - 2023 - researchsquare.com
Parathyroid carcinoma (PC) is a rare and aggressive endocrine malignancy with limited
treatment options. Despite the lack of standard management approaches to prevent …
treatment options. Despite the lack of standard management approaches to prevent …